European Regulatory Round-Up: Collaborations And Conflicts Of Interest
The European Union hopes to streamline procedures for small drug companies, including through electronic submissions and also calls for a collaborative approach to fight antbiotic resistance; French Senate tightens down on health regulators conflicts of interest.
You may also be interested in...
French Senate offers a class action mechanism that could impose a 50% penalty on drug firms.
A survey showing improvement in the pipeline for new antibiotics could further the growing momentum for legislation that would create more development incentives.
MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins
In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.